Arvinas Secures FDA Approval for First-in-Class PROTAC VEPPANU, Triggers $50M Milestone Payment
ARVN sits 74% above its 52-week low of $5.9 on light trading volume (0.3× avg).
Summary
Arvinas announced FDA approval for VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader, for advanced breast cancer, triggering a $50 million milestone payment from Pfizer.
Key Events · Product Development and Regulatory · ARVN
-
FDA Approves VEPPANU
The U.S. Food and Drug Administration (FDA) granted approval for VEPPANU (vepdegestrant) for the treatment of ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer.
-
First-Ever PROTAC Approval
VEPPANU is the first and only FDA-approved PROteolysis Targeting Chimera (PROTAC) protein degrader, validating Arvinas's core technology platform.
-
$50 Million Milestone Payment
Arvinas will receive a $50.0 million development milestone payment from Pfizer Inc. in connection with the FDA approval.
-
Early Approval
The approval was received ahead of the FDA-assigned Prescription Drug User Fee Act (PDUFA) date of June 5, 2026.
Analysis · ARVN · Life Sciences
This FDA approval for VEPPANU is a transformative event for Arvinas, marking its first approved medicine and validating its pioneering PROTAC technology. The approval, received ahead of schedule, addresses a significant unmet medical need in ESR1-mutated, ER+/HER2- advanced breast cancer. The $50 million milestone payment from Pfizer provides a substantial cash inflow, further strengthening the company's financial position and supporting its ongoing commercialization strategy with Pfizer and a planned third-party partner. This milestone significantly de-risks the company's pipeline and provides a strong foundation for future growth.
At the time of this filing, ARVN was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $656.9M. The 52-week trading range was $5.90 to $14.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.